^
Association details:
| Biomarker: | CCR7 positive |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Tecartus (brexucabtagene autoleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
413 - Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
Published date:
01/13/2021
Excerpt:
...ORR/CR rates were as follows: Ibr 94%/65%; Acala 80%/40%; both 100%/100%. The 12-mo survival rates in pts with prior Ibr, Acala, or both were 81%, 80%, or 100%, respectively. Grade ≥ 3 CRS/NEs occurred as follows: Ibr 17%/31%; Acala 10%/10%; both 0/67%. All subgroups drew clinical benefit from KTE-X19 treatment despite some pharmacological differences.
Trial ID:
